These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34593162)

  • 41. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Future drug prices and cost-effectiveness analyses.
    Hoyle M
    Pharmacoeconomics; 2008; 26(7):589-602. PubMed ID: 18563950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.
    McGowan B; Bennett K; Tilson L; Barry M
    Ir Med J; 2005 Mar; 98(3):78-80. PubMed ID: 15869064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drugs cheaper than threepenny: the market of extremely low-priced drugs within the National Health Insurance in Taiwan.
    Wang BR; Chou CL; Hsu CC; Chou YC; Chen TJ; Chou LF
    ScientificWorldJournal; 2014; 2014():234941. PubMed ID: 24719568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.
    Lee IH; Bloor K; Hewitt C; Maynard A
    J Health Serv Res Policy; 2015 Jan; 20(1):52-9. PubMed ID: 25092883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The drug budget silo mentality: the Dutch case.
    Koopmanschap MA; Rutten FF
    Value Health; 2003; 6 Suppl 1():S46-51. PubMed ID: 12846925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
    Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
    PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand.
    Isaranuwatchai W; Nakamura R; Wee HL; Sarajan MH; Wang Y; Soboon B; Lou J; Chai JH; Theantawee W; Laoharuangchaiyot J; Mongkolchaipak T; Thathong T; Kingkaew P; Tungsanga K; Teerawattananon Y
    PLoS One; 2022; 17(10):e0274944. PubMed ID: 36191016
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.
    Gissel C; Götz G; Repp H
    Z Rheumatol; 2016 Dec; 75(10):1006-1015. PubMed ID: 27080399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast.
    Cowley P
    Health Policy; 1993 May; 24(2):145-53. PubMed ID: 10128800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
    Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
    Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.